Angiotensin News and Research RSS Feed - Angiotensin News and Research

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.
Research shows women have more risk factors for heart disease

Research shows women have more risk factors for heart disease

Despite messages to the contrary, most women being seen by a doctor for the first time with suspected heart disease actually experience the same classic symptoms as men, notably chest pain and shortness of breath, according to a study led by the Duke Clinical Research Institute. [More]
Researchers discover unexpected mechanism linked to aldosterone-induced heart damage

Researchers discover unexpected mechanism linked to aldosterone-induced heart damage

When the heart begins to fail, the body does everything in its power to fix the situation. But sometimes, those compensatory mechanisms ultimately do more harm than good. Such is the case with the adrenal hormone aldosterone, which stimulates the heart to pump harder, causing greater damage to the heart muscle. [More]
Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. [More]
Low-sodium intake has little impact on bone health in postmenopausal women

Low-sodium intake has little impact on bone health in postmenopausal women

A low-salt diet does not necessarily translate to stronger bones in postmenopausal women, physician-scientists report. [More]
Gene expression analysis points metastatic CRC patient to successful irbesartan therapy

Gene expression analysis points metastatic CRC patient to successful irbesartan therapy

A patient with recurrent metastatic colorectal cancer has been successfully treated with the angiotensin receptor blocker irbesartan, researchers report. [More]
Tackling insulin resistance may reduce recurrence after stroke

Tackling insulin resistance may reduce recurrence after stroke

Giving pioglitazone to stroke survivors with insulin resistance but no overt diabetes reduces their risk of having a recurrent vascular event, shows the randomised Insulin Resistance Intervention after Stroke trial. [More]
Iroko announces availability of VIVLODEX capsules in U.S. pharmacies for patients with OA pain

Iroko announces availability of VIVLODEX capsules in U.S. pharmacies for patients with OA pain

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced today that VIVLODEX (meloxicam) capsules, a nonsteroidal anti-inflammatory drug (NSAID), is now available by prescription at pharmacies across the United States. [More]
Older people could be at greater risk for negative consequences of consuming high-salt diet

Older people could be at greater risk for negative consequences of consuming high-salt diet

Aging is associated with a number of changes that cause the body to function less efficiently, including the way the body controls water and sodium levels. Research has shown that as humans and animals age, they are less able to regulate sodium and water retention, urine concentration and thirst compared to their younger counterparts. [More]
FDA-approved blood pressure drug reduces cell damage linked to Alzheimer's disease

FDA-approved blood pressure drug reduces cell damage linked to Alzheimer's disease

In laboratory neuronal cultures, an FDA-approved drug used to treat high blood pressure reduced cell damage often linked to Alzheimer's disease, say researchers at Georgetown University Medical Center and the National Institutes of Health. [More]
FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients. [More]
Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced positive results of an open label clinical study evaluating the pharmacodynamic (PD) activity of RDX022 in healthy adult volunteers. [More]
Case Western scientist to lead a pair of studies to develop more effective treatment for CF

Case Western scientist to lead a pair of studies to develop more effective treatment for CF

A scientist at Case Western Reserve University Frances Payne Bolton School of Nursing will lead a pair of studies to develop more effective treatment for symptoms of cystic fibrosis (CF), a life-threatening genetic disease that causes persistent lung infections and progressively limits the ability to breathe. [More]
Doctors in Mexico show benefits of healthy diet, exercise in heart failure patients

Doctors in Mexico show benefits of healthy diet, exercise in heart failure patients

Doctors in Mexico have shown the benefits of a healthy diet and exercise in patients with heart failure, in research presented at the Mexican Congress of Cardiology 2015. [More]
New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals, Inc. today announced new study data that shows the company's FDA-approved drug DURLAZA delivers sustained antiplatelet control for a full 24-hour period in high-risk patients. [More]
Circulating protein predicts risk of chronic kidney disease

Circulating protein predicts risk of chronic kidney disease

Make room, cholesterol. A new disease marker is entering the medical lexicon: suPAR, or soluble urokinase-type plasminogen activator receptor. [More]
Study reveals poor levels of use, availability and affordability of cardiovascular disease medicines worldwide

Study reveals poor levels of use, availability and affordability of cardiovascular disease medicines worldwide

New research published in The Lancet shows that the use of vital life-saving generic (and supposedly inexpensive) medicines for prevention in people with existing heart disease is poor worldwide. In low-income and middle-income countries these medicines are not widely available and, when available, can often be unaffordable. In rich countries, although such medicines are both available and affordable, 35% to 50% of patients who have heart disease or a previous stroke still do not receive them. [More]
Radical shift required in use of heart medicine worldwide

Radical shift required in use of heart medicine worldwide

Many people in the world who need essential heart medicine do not get it, even in rich countries, says new research published today in the medical journal The Lancet. [More]
Veltassa (patiromer for oral suspension) gets FDA approval for treatment of hyperkalemia

Veltassa (patiromer for oral suspension) gets FDA approval for treatment of hyperkalemia

The U.S. Food and Drug Administration today approved Veltassa (patiromer for oral suspension) to treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high. [More]
Cardiac monitoring predicts survival in patients with Friedreich ataxia

Cardiac monitoring predicts survival in patients with Friedreich ataxia

Researchers confirm the need for cardiac follow-up in patients with Friedreich ataxia, with particular focus on left ventricular ejection fraction as a predictor of worse prognosis. [More]
High levels of satiety hormone leptin contribute to cardiovascular disease in obese individuals

High levels of satiety hormone leptin contribute to cardiovascular disease in obese individuals

While high levels of the satiety hormone leptin don't help obese individuals lose weight, they do appear to directly contribute to their cardiovascular disease, researchers report. [More]
Advertisement
Advertisement